Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAK4 | O96013 | 1/20 | 0.37 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.37 |
| ▸ | KARS1 | Q15046 | 2/20 | 0.36 |
| ▸ | CAMK1D | Q8IU85 | 3/20 | 0.35 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.33 |
| ▸ | LCK | P06239 | 1/20 | 0.33 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.33 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | MELK | Q14680 | 1/20 | 0.31 |
| ▸ | AURKA | O14965 | 1/20 | 0.31 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.30 |
| ▸ | CDC42BPB | Q9Y5S2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8429895 | 0.96 | PAK4 (0.42) | PAK4PAK1KARS1CAMK1DROCK2 | |
| SCHEMBL8429786 | 0.89 | BTK (0.34) | HRH4HRH3SYKMELKAURKA | |
| SCHEMBL8429587 | 0.88 | ADORA3 (0.38) | HRH4LCKPTK6AURKBADORA3 | |
| SCHEMBL8426788 | 0.80 | AURKA (0.35) | ADORA3AURKA | |
| SCHEMBL14536838 | 0.79 | AURKA (0.51) | PAK4PAK1KARS1LCKPTK6 | |
| SCHEMBL8239859 | 0.79 | AURKA (0.51) | PAK4PAK1KARS1LCKPTK6 | |
| SCHEMBL8427844 | 0.77 | KCNH2 (0.36) | HRH4PTK6HRH3SYKADORA3 | |
| SCHEMBL8427744 | 0.76 | MAPKAPK5 (0.38) | PTK6SYKADORA3AURKA | |
| SCHEMBL12473231 | 0.74 | AURKA (0.34) | AURKBSYKADORA3AURKA | |
| SCHEMBL8427741 | 0.73 | BRD4 (0.39) | KARS1SYKADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7576085-B2 | Imidazopyrazines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2009-08-18 | — | — | US | disclosed |
| US-20070105864-A1 | Methods for inhibiting protein kinases | SCHERING CORPORATION | 2007-05-10 | — | — | US | disclosed |
| US-20060106023-A1 | Novel imidazopyrazines as cyclin dependent kinase inhibitors | SCHERING CORPORATION | 2006-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106023-A1 | Novel imidazopyrazines as cyclin dependent kinase inhibitors | CDK2, CDKN1A, CDK1 | PAK4 247/4885PAK1 169/4885KARS1 1657/4885 |
| US-20070105864-A1 | Methods for inhibiting protein kinases | PIM1, PIM2, PIM3 | PAK4 508/4885PAK1 217/4885KARS1 1217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.